Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Barclays Maintains Overweight on NuVasive, Raises Price Target to $58

Author: Benzinga Newsdesk | August 04, 2023 07:08am
Barclays analyst Matt Miksic maintains NuVasive (NASDAQ:NUVA) with a Overweight and raises the price target from $56 to $58.

Posted In: NUVA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist